Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.
Patient transfer from nursing home to emergency department: outcomes and policy implications.